Εμφανίζονται 1 - 20 Αποτελέσματα από 32 για την αναζήτηση '"бронхолитическая терапия"', χρόνος αναζήτησης: 0,62δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
    Academic Journal

    Πηγή: Siberian journal of oncology; Том 22, № 5 (2023); 49-59 ; Сибирский онкологический журнал; Том 22, № 5 (2023); 49-59 ; 2312-3168 ; 1814-4861

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/2760/1158; Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009; 34(2): 380–6. doi:10.1183/09031936.00144208.; Kondo R., Yoshida K., Eguchi T., Kobayashi N., Saito G., Hamanaka K., Shiina T., Kurai M. Clinical features of lung cancer in smokers with light and mild chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases. Eur J Cardiothorac Surg. 2011; 40(6): 1439–43. doi:10.1016/j.ejcts.2011.03.017.; Vermaelen K., Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther. 2013; 26(5): 544–54. doi:10.1016/j.pupt.2013.05.003.; Murakami J., Ueda K., Sano F., Hayashi M., Nishimoto A., Hamano K. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res. 2016; 200(2): 690–7. doi:10.1016/j.jss.2015.09.004.; Добнер С.Ю., Федосенко С.В., Родионов Е.О., Яровой Н.Д., Петров В.А., Тузиков С.А., Старовойтова Е.А., Самыкина И.А. Рак легкого у больных ХОБЛ и факторы, ассоциированные со снижением их выживаемости. Бюллетень сибирской медицины. 2022; 21(3): 41–9. doi:10.20538/16820363-2022-3-41-49.; Brunelli A., Kim A.W., Berger K.I., Addrizzo-Harris D.J. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 s): 166–90. doi:10.1378/chest.12-2395. Erratum in: Chest. 2014; 145(2): 437.; Белялова Н.С., Дворниченко В.В., Менг А.А., Моклоков А.В., Лелявин Б.И., Сокольников М.В., Улыбин П.С., Хаматов Р.К. Факторы риска хирургии легких: возраст и респираторная функция. Российский онкологический журнал. 2009; (1): 48–9.; Adcock I.M., Caramori G., Barnes P.J. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011; 81(4): 265–84. doi:10.1159/000324601.; Roy E., Rheault J., Pigeon M.A., Ugalde P.A., Racine C., Simard S., Chouinard G., Lippens A., Lacasse Y., Maltais F. Lung cancer resection and postoperative outcomes in COPD: A single-center experience. Chron Respir Dis. 2020; 17. doi:10.1177/1479973120925430.; Venkatesan P. GOLD COPD report: 2023 update. Lancet Resp Med. 2022; 11(1). doi:10.1016/S2213-2600(22)00494-5.; González J., Henschke C.I., Yankelevitz D.F., Seijo L.M., Reeves A.P., Yip R., Xie Y., Chung M., Sánchez-Salcedo P., Alcaide A.B., Campo A., Bertó J., Del Mar Ocón M., Pueyo J., Bastarrika G., de-Torres J.P., Zulueta J.J. Emphysema phenotypes and lung cancer risk. PLoS One. 2019 Jul 25; 14(7). doi:10.1371/journal.pone.0219187.; Akira M., Toyokawa K., Inoue Y., Arai T. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. Am J Roentgenol. 2009; 192(1): 267–72. doi:10.2214/AJR.07.3953.; https://www.siboncoj.ru/jour/article/view/2760

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
    Academic Journal

    Πηγή: PULMONOLOGIYA; № 5 (2011); 34-37 ; Пульмонология; № 5 (2011); 34-37 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2011-0-5

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/379/376; Национальная программа: Бронхиальная астма у детей. Стратегия лечения и профилактика. 3-е изд. М.; 2008.; Чучалин А.Г. (ред.). Рациональная фармакотерапия заболеваний органов дыхания. Руководство для практикующих врачей. М.: Литтерра; 2004.; O'Driscoll B.R., Taylor R.J., Horsley M.G. et al. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1: 1418–1420.; Rodrigo G., Castro)Rodriguez J. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60 (9): 740–746.; Геппе Н.А. Ингаляционная небулайзерная терапия заболеваний респираторной системы у детей: Практ. руководство для врачей. М.; 2008.; Stoodley R.G., Aaron S.D., Dales R.E. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a meta-analysis of randomized clinical trials. Ann. Emerg. Med. 1999; 34: 8–18.; Plotnick L.H., Ducharme F.M. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst. Rev. 2000; 4: CD000060.; https://journal.pulmonology.ru/pulm/article/view/379

  12. 12
    Academic Journal

    Συγγραφείς: N. M. Nenasheva, Н. М. Ненашева

    Πηγή: PULMONOLOGIYA; № 6 (2011); 111-115 ; Пульмонология; № 6 (2011); 111-115 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2011-0-6

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/427/427; Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci.1993; 52 (26): 2145–2160.; Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir. Med. 2001; 95 (Suppl. B): S7–S11.; GINA, 2010. http://www.ginasthma.com; Mitchell C., Jenkins C, Scicchitano R, Rubinfeld A. Adding formoterol is more effective and safer than doubling the dose of inhaled steroids in moderately severe asthma. Am. J. Respir. Crit. Care Med. 2000; 161: A197 (abstr.).; Black J.L., Oliver B.G.G., Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists. Chest 2009; 136: 1095–1100.; Grainge C, Lau L., Ward J. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364: 2006–2015.; Chowdhury B.A., Dal Pan G. The FDA and safe use of longacting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010; 362: 1169–1171.; GOLD, 2010. http://www.goldcopd.com; Sears M.R. Long-acting bronchodilators in COPD. Chest 2008; 133: 1057–1058.; Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: A systematic review. Chest 2008; 133: 1079–1087.; Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Res. Med. 2008; 102: 1701–1707.; Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Res. Med. 1998; 92 (Suppl. A): 23–31.; Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343–351.; Busse W.W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionat in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. 1999; 104: 1215–1222.; Цой А.Н. Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата / формотерола: слагаемые успеха. Consilium Medicum 2008; прил. "Болезни органов дыхания": 39–45.; Bousquet J., Huchon G., Leclerc V. et al. A randomized double-blind, double-dummy, single-dose efficacy crossover trial comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 6–12.; Мещерякова Н.Н., Белевский А.С. Атмосфера. Пульмонол. и аллергол. 2007; 4: 32–35.; De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP / Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148.; https://journal.pulmonology.ru/pulm/article/view/427

  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20